UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 14, 2007
Hana Biosciences, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-32626 | 32-0064979 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
7000 Shoreline Court, Suite 370, South San Francisco, CA | 94080 |
| (Address of principal executive offices) | (Zip Code) |
(650) 588-6404
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 14, 2007, pursuant to authorization of the Board of Directors of Hana Biosciences, Inc. (the “Company”), the Company awarded stock options pursuant to its 2004 Stock Incentive Plan to Steven R. Deitcher, the Company’s President and CEO, and John P. Iparraguirre, the Company’s Vice President, Chief Financial Officer. Dr. Deitcher was awarded an option to purchase 650,000 shares of common stock, and Mr. Iparraguirre received an option to purchase 110,000 shares. Each option has a term of 10 years, vests in three equal annual installments commencing December 14, 2008 and is exercisable at a price of $1.12 per share. The options are evidenced by an agreement in the form attached to the Company’s Annual Report on Form 10-K for the year ended December 31, 2006 as Exhibit 10.2.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | Hana Biosciences, Inc. |
|
|
|
| Date: December 20, 2007 | By: | /s/ John P. Iparraguirre |
| |
John P. Iparraguirre Vice President, Chief Financial Officer |
| | |
